India's Medicine QR Codes Must Move to Uniform Global Data Standards: GS1 CEO

India's Expanding Medicine QR Code Deadlines

India's medicine packaging rules are moving from a limited pilot to a broad regulatory requirement. An earlier 2022 decision already required 300 top-selling drug brands to carry QR or bar codes from August 2023. The government has now extended the mandate: cancer drugs, narcotics, psychotropic drugs and vaccines must carry QR codes by July 1, 2027, and antimicrobials by July 1, 2028.

Under the Health Ministry's guidance, each code must give consumers nine data elements: the unique product identification code, proper and generic drug names, brand name, manufacturer's name and address, batch number, manufacture date, expiry date, manufacturing licence number and excipient details. The ministry says digital authentication will support seamless verification and tracking of medicines across the supply chain.

GS1 India chief executive S Swaminathan says that consumer-facing product information is only the first step. For the system to spot counterfeits and support recalls, every link — warehouse, distributor, stockist and chemist — must read the data in the same way. At present, he says, the domestic market still lacks that uniform presentation of information, even though exporters are already aligned with international standards.

Why GS1 India Says Standardisation Is the Next Leap

What the Nine Data Fields Do — and Where They Stop

The listed nine fields are a genuine step forward: a pharmacist or consumer can verify the medicine's identity, batch and expiry without calling the manufacturer. But the format matters. If one company encodes the batch number one way and another uses a different structure, a warehouse scanner may capture only some of the data, or none at all. Swaminathan's argument is that the current rule specifies what information must be present, but not yet the common structure needed for machines to exchange it reliably.

Why the Domestic and Export Markets Are Drifting Apart

Export-oriented manufacturers already use international product-coding standards because overseas buyers demand them. Domestic production is not under the same commercial pressure. GS1 India — set up by the Commerce Ministry and industry bodies as an affiliate of GS1 Global — is pushing for the domestic system to adopt the same universal product, batch and expiry encoding. Otherwise India risks a two-speed supply chain in which exported medicines are easier to trace than those sold at home.

The Medical Device Gap Is Even Wider

Swaminathan rates India's track-and-trace journey at only 2 on a scale of 10. The medicine mandate gives the pharmaceutical industry until 2027 and 2028 to build the necessary linkages, but medical devices are at an earlier stage, suggesting future regulatory attention and heavier catch-up work for device makers.

What Pharma Firms, Distributors and Chemists Should Do Before 2027

For companies and supply-chain operators, the 2027 and 2028 deadlines leave time to act, but only if work starts before the rules are finalised.

• Pharmaceutical manufacturers: Map oncology, narcotic, psychotropic, vaccine and antimicrobial products against the two deadlines, and build packaging lines around the nine data elements using a globally recognised code structure, not a proprietary domestic format.
• Distributors and stockists: Test whether warehouse scanners can read QR data uniformly across multiple manufacturers, and flag suppliers whose codes do not return the mandatory batch, expiry and licence fields.
• Retail chemists: Prepare scanning and verification workflows for the codes before the legal dates, since counterfeit and recall checks will depend on consistent data at the point of dispensation.
• Medical device makers: Treat the current medicine-focused mandate as a signal that device traceability is the next regulatory frontier, and begin aligning device data structures with GS1 standards now.